5-HT receptors (Serotonin receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems.5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 are the types. Both excitatory and inhibitory neurotransmission is mediated by them. The neurotransmitter serotonin, which serves as their inherently ligand, stimulates the serotonin receptors. Numerous neurotransmitters and hormones are released in response to stimulation of the serotonin receptors. Numerous biological and neurological functions, including aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation, are influenced by serotonin receptors. Many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens are among the pharmaceuticals that target the serotonin receptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3895 | Palonosetron | 135729-61-2 | Palonosetron (formerly RS-25259, RS-25259 197; trade name:Aloxi andAkynzeo) is a 5-HT3 antagonist approved for use in the prevention and treatment of chemotherapy-induced nausea and vomiting. |
|
V1022 | Palonosetron HCl (RS25233-197; Aloxi) | 135729-62-3 | Palonosetron HCl (formerly RS-25259, RS-25259,RS 25259 197, RS-25259197; trade names:Aloxi andAkynzeo), an approved antiemetic drug, is a potent 5-HT3 antagonist that has been used in the prevention and treatment of chemotherapy-induced nausea and vomiting. |
|
V71195 | Palonosetron-d3 hydrochloride (palonosetron d3 hydrochloride (HCl)) | 1246816-81-8 | Palonosetron-d3 ( HCl) is the deuterium labelled form of Palonosetron HCl. |
|
V3783 | Pardoprunox | 269718-84-5 | Pardoprunox (formerly known as SLV-308, DU-126891 or SME-308) is novel & potent dopamine D2/5-HT1A receptor agonist that has the potential for the treatment of Parkinson's disease. |
|
V3008 | Pardoprunox HCI | 269718-83-4 | Pardoprunox (formerly known as SLV-308, DU-126891 or SME-308) is novel & potent dopamine D2/5-HT1A receptor agonist that has the potential for the treatment of Parkinsons disease. |
|
V27338 | PF-04995274 | 1331782-27-4 | PF-04995274 (PF04995274) is a novel and potent serotonin 4 receptor (5-HT4) partial agonist,acting centrally as a pro-cognitive agent with the potential to be used for the treatment of Alzheimers disease (AD). |
|
V4625 | Piboserod | 152811-62-6 | Piboserod (SB 207266; trade name Serlipet) is a novel, potent and selective 5-HT(4) receptor antagonist marketed by GSK. |
|
V3349 | Pimavanserin | 706779-91-1 | Pimavanserin (formerly ACP-103; BVF-036; trade name Nuplazid) is an orally bioactive and selective inverse agonist of the 5-HT2A (serotonin receptor subtype 2A, pIC50 and pKd of 8.73 and 9.3, respectively)receptor approved asan atypical antipsychotic for the treatment of Parkinsons disease psychosis. |
|
V3350 | Pimavanserin tartrate | 706782-28-7 | Pimavanserin tartrate (formerly known as BVF036; ACP-103; BVF-036; Nuplazid), the tartrate salt of Pimavanserin, is a novel and orally bioactive inverse agonist of the 5-HT2A (serotonin receptor subtype 2A) receptor the has been approved in 2016 as an atypical antipsychotic for the treatment of Parkinson's disease psychosis. |
|
V5162 | Pindolol (LB-46) | 13523-86-9 | Pindolol (known also as LB-46), a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, is an aryloxypropanolamine derivative with antihypertensive property. |
|
V71228 | Pindolol-d7 (Pindolol d7) | 1185031-19-9 | Pindolol-d7 is the deuterated form of Pindolol. |
|
V1036 | Prucalopride (R-108512, R-93877) | 179474-81-8 | Prucalopride (Motegrity; R-108512; R 108512;Resolor; Resotran; R108512; Prudac),a novel enterokinetic compound andthe first representative drug of the benzofuran class oflaxatives, is a selective and high affinity 5-HT (serotonin) receptor agonist withKis of 2.5 nM and 8 nM for 5-HT4A and 5-HT4B receptor, respectively. |
|
V0973 | Prucalopride Succinate (R-108512, R-93877) | 179474-85-2 | Prucalopride (R 108512; R108512; R 108512; trade names: Resolor; Resotran; Motegrity),a novel enterokinetic and benzofuran-based compound, is a novel, selective, high affinity 5-HT (serotonin) receptor agonist for 5-HT4A and 5-HT4B receptor with anti-idiopathic constipation activity. |
|
V2617 | PRX-08066 | 866206-54-4 | PRX-08066 is a potent andselective 5-HT2B receptor antagonist with IC50 of 3.4 nM, it prevents the severity of pulmonary arterial hypertension in the MCT rat model. |
|
V0969 | PRX-08066 Maleic acid | 866206-55-5 | PRX-08066 maleic acid (MT500; MT-500; PRX 08066; PRX08066), the maleic acid salt of PRX08066, is a novel, potent and selective 5-HT2B receptor antagonist with important biological activity. |
|
V2391 | Puerarin (Kakonein) | 3681-99-0 | Puerarin (Kakonein), a naturally occuring isoflavone isolated from the root of Radix puerariae, is a 5-HT2C receptor and benzodiazepine site antagonist. |
|
V9837 | Quetiapine | 111974-69-7 | Quetiapine Fumarate (also known as ICI-204636; trade name Seroquel) is a dibenzothiazepine-based atypical antipsychotic agent acting as a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. |
|
V1282 | Quetiapine Fumarate (ICI 204636)) | 111974-72-2 | Quetiapine Fumarate (Seroquel XR; IC-204,636; ICI204,636; ICI-204636), the fumarate salt of Quetiapine, is an atypical antipsychotic drug used for the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression. |
|
V71211 | Quetiapine-d8 fumarate (quetiapine d8 fumarate) | 1185247-12-4 | Quetiapine-d8 (fumarate) is the deuterated form of Quetiapine hemifumarate. |
|
V78945 | Quetiapine-d8 hemifumarate (quetiapine d8 (hemifumarate)) | Quetiapine-d8 (hemifumarate) is the deuterated form of Quetiapine hemifumarate. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
